MEREDITH XIMINES-MULLINGS: Open Payments
NPI 1972385102 · LONGWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,039 in 25 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $905 · 2025 $1,039
Food & beverage: $1,039
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $243 |
| E.R. Squibb & Sons, L.L.C. | 3 | $173 |
| Janssen Pharmaceuticals, Inc | 2 | $171 |
| Teva Pharmaceuticals USA, Inc. | 6 | $123 |
| Otsuka America Pharmaceutical, Inc. | 1 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| ACADIA Pharmaceuticals Inc | 1 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
Products named: COBENFY, SPRAVATO, HETLIOZ, FANAPT, REXULTI, AUSTEDO XR, CAPLYTA, NUPLAZID.
Industry payments across FL — which companies pay providers there.
